Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma

Ricardo Robles, Joan Figueras, Victor S Turrión, Carlos Margarit, Angel Moya, Evaristo Varo, Javier Calleja, Andres Valdivieso, Juan Carlos G Valdecasas, Pedro López, Manuel Gómez, Emilio de Vicente, Carmelo Loinaz, Julio Santoyo, Manuel Fleitas, Angel Bernardos, Laura Lladó, Pablo Ramírez, F S Bueno, Eduardo Jaurrieta, Pascual Parrilla, Ricardo Robles, Joan Figueras, Victor S Turrión, Carlos Margarit, Angel Moya, Evaristo Varo, Javier Calleja, Andres Valdivieso, Juan Carlos G Valdecasas, Pedro López, Manuel Gómez, Emilio de Vicente, Carmelo Loinaz, Julio Santoyo, Manuel Fleitas, Angel Bernardos, Laura Lladó, Pablo Ramírez, F S Bueno, Eduardo Jaurrieta, Pascual Parrilla

Abstract

Objective: To assess the real utility of orthotopic liver transplantation (OLT) in patients with cholangiocarcinoma, we need series with large numbers of cases and long follow-ups. The aim of this paper is to review the Spanish experience in OLT for hilar and peripheral cholangiocarcinoma and to try to identify the prognostic factors that could influence survival.

Summary background data: Palliative treatment of nondisseminated irresectable cholangiocarcinoma carries a zero 5-year survival rate. The role of OLT in these patients is controversial, due to the fact that the survival rate is lower than with other indications for transplantation and due to the lack of organs.

Methods: We retrospectively reviewed 59 patients undergoing OLT in Spain for cholangiocarcinoma (36 hilar and 23 peripheral) over a period of 13 years. We present the results and prognostic factors that influence survival.

Results: The actuarial survival rate for hilar cholangiocarcinoma at 1, 3, and 5 years was 82%, 53%, and 30%, and for peripheral cholangiocarcinoma 77%, 65%, and 42%. The main cause of death, with both types of cholangiocarcinoma, was tumor recurrence (present in 53% and 35% of patients, respectively). Poor prognosis factors were vascular invasion (P < 0.01) and IUAC classification stages III-IVA (P < 0.01) for hilar cholangiocarcinoma and perineural invasion (P < 0.05) and stages III-IVA (P < 0.05) for peripheral cholangiocarcinoma.

Conclusions: OLT for nondisseminated irresectable cholangiocarcinoma has higher survival rates at 3 and 5 years than palliative treatments, especially with tumors in their initial stages, which means that more information is needed to help better select cholangiocarcinoma patients for transplantation.

References

    1. Madariaga JR, Iwatsuki S, Todo S, et al. Liver resection for hilar and peripheral cholangiocarcinomas. Ann Surg. 1998;227:70.
    1. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihiliar and distal tumor. Ann Surg. 1996;224:463.
    1. Jarnagin WR, Fong Y, De Matteo RP, et al. Staging, resectability and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507.
    1. Miyazaki M, Ito H, Nakayama K, et al. Parenchima-preserving hepatectomy in the surgical treatment of hilar cholangiocarcinoma. J Am Coll Surg. 1999;189:575.
    1. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg. 1992;215:31.
    1. Klempnauer J, Ridder GJ, Von Wasilewski R, et al. Resection surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factor. J Clin Oncol. 1997;15:947.
    1. Washburn WK, Lewis D, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg. 1995;130:270.
    1. Kurshinoff BW, Armtrong JG, Fong Y, et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br J Surg. 1995;82:1522.
    1. Figueras J, Lladó L, Valls C, et al. Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transplant. 2000;6:786.
    1. Busuttil RW, Farmer DG. The surgical treatment of primary hepatobiliary malignancy (review). Liver Tranpl Surg. 1996;2(suppl. 1):114.
    1. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation. 2000;69:1633.
    1. Iwatsuki S, Todo S, Marsh W, et al. Treatment of hilar cholangiocarcinoma (Klastkin tumors) with hepatic resection or transplantation. J Am Coll Surg. 1998;187:358.
    1. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet. 1975;140:170.
    1. Sobin LH, Wittekind CH, eds. TNM classification of management tumors, 5th ed, New York: Wiley, 1997:81.
    1. Tsao JI, Nimura Y, Kamiya J, et al. Management of hilar cholangiocarcinoma. Comparison of an American and Japanese experience. Ann Surg. 2000;232:166.
    1. Launois B, Terblanche J, Lakehal M, et al. Proximal bile duct cancer: high respectability rate and 5-year survival. Ann Surg. 1999;230:266.
    1. Reed DN, Vitale GC, Martín R, et al. Bile duct carcinoma: trends in treatment in the nineties. Am Surg. 2000;66:711.
    1. Ogura Y, Kawarada Y. Surgical strategies for carcinoma of the hepatic duct confluence. Br J Surg. 1998;85:20.
    1. Nimura Y, Hayakawa N, Kamiya J, et al. Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus. W. J Surg. 1990;14:535.
    1. Kosuge T, Yamamoto J, Shimada K, et al. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg. 1999;230:663.
    1. Neuhaus P, Jonas S, Bechstein WO, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg. 1999;230:808.
    1. Tsukada K, Yoshida K, Aono T, et al. Major hepatectomy and pancreatoduodenectomy for advanced carcinoma of the biliary tract. Br J Surg. 1994;81:108.
    1. Neuhaus P, Blumhardt G. Extended bile duct resection: a new oncological approach to the treatment of central bile duct carcinomas? Langenbecks Arch Surg. 1994;379:123.
    1. Starzl TE, Todo S, Tzakis AG, et al. Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg. 1989;210:374.
    1. Casavilla FA, Marsh JW, Iwatsuki S. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg. 1998;185:429.
    1. Gores GJ. Early detection and treatment of cholangiocarcinoma. Liver Transplant. 2000;6:30.
    1. Nashan B, Schlitt HJ, Tusch G, et al. Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation. Hepatology. 1996;23:1105.
    1. De Vreede I, Steer JL, Burch PA, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transplant. 2000;6:309.
    1. Bismuth H. Revisiting liver transplantation for patients with hilar cholangiocarcinoma: the Mayo Clinic proposal. Liver Transplant. 2000;6:317.
    1. Berdah SV, Delpero JR, Garcia S, et al. A western surgical experience of peripheral cholangiocarcinoma. Br J Surg. 1996;83:1517.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe